MedTrace Logo

Effects of Dietary Interventions on Serum and Macrophage Atherogenicity

NCT02894931 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2016-09-27

No results posted yet for this study

Summary

While previous atherosclerosis-related studies have focused mainly on the atherogenicity of lipids, the proposed study aims to investigate the effects of other dietary factors, i.e. monosaccharides, disaccharides, amino acids, or artificial sweeteners, on the atherogenicity of serum or macrophages. Findings from the current proposed study may shed light on yet unknown mechanisms by which the above dietary factors could affect atherosclerosis development and CVD risk and hence could possibly assist in the future development of anti-atherogenic strategies.

Conditions

Interventions

DIETARY_SUPPLEMENT

monosaccharides

The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.

DIETARY_SUPPLEMENT

Disaccharides

The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.

DIETARY_SUPPLEMENT

Amino acids

The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.

DIETARY_SUPPLEMENT

Artificial Sweeteners

The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.

OTHER

Control- water

Chilled water flavored with lemon juice as control

Sponsors & Collaborators

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Tony Hayek, Prof. · Rambam Health care center

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-05-31
Completion
2018-08-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02894931 on ClinicalTrials.gov